Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SynAct Pharma AB ( (SE:SYNACT) ) has provided an announcement.
SynAct Pharma AB has called its annual general meeting for 11 June 2026 in Stockholm, inviting shareholders to participate in person or by proxy subject to registration with Euroclear Sweden and timely notification to the company. The agenda covers standard governance matters, including board and auditor elections, approval of remuneration guidelines, and an authorization for potential new share issues.
The board proposes that no dividend be distributed for the past financial year, with all available funds carried forward to support the company’s operations and development activities. This decision underscores a continued focus on reinvesting capital into the business rather than returning cash to shareholders, which may signal prioritization of growth over near-term yield for investors.
More about SynAct Pharma AB
SynAct Pharma AB is a Swedish biotechnology company based in Lund, focused on developing treatments for inflammatory and autoimmune diseases. The company operates in the life sciences sector and is listed on the Swedish market, with a shareholder base that includes institutional and private investors.
Average Trading Volume: 219,964
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK778.6M
See more data about SYNACT stock on TipRanks’ Stock Analysis page.